Johnson & Johnson Phase 3 Data Released: One Job, 72% Effectiveness

The COVID-19 vaccine, the third major option for Johnson & Johnson, published its Phase 3 interim analysis data on Friday. The vaccine is named ENSEMBLE.

ENSEMBLE, noted for being a single-dose vaccine, showed effectiveness in 72% of 43,783 recipients participating in Phase 3 trials.

CEO Alex Gorski said, “Our goal is to create a simple, effective solution for the greatest number of all people, and help end the epidemic.”

Of the participants, there were 468 symptomatic COVID-19 cases. These people were reviewed 14 to 28 days after injection.

“Too good doesn’t get in the way,” Kizzmekia Corbett, one of the vaccine developers for Modern, tweeted on Friday, encouraged by ENSEMBLE’s efficacy percentage.

The data showed that starting on the 14th day, and ending completely after 28 days of vaccination, recipients were moderate to 66% safe for severe complications from COVID-19, so that if any 28 Getting this vaccine even if the virus is caught within days, the effect will not be severe, 66% of the time.

The declaration notes that “the results of the ENSEMBLE study included efficacy against newly emerging strains of coronovirus, including some highly infectious variants present in the US, Latin America, and South Africa.”

The efficacy rate of the vaccine dropped significantly from the United States, where it ranged from 72%, to 57%, in South Africa, where a new variant was recently discovered, which was of global concern. The recent closure of the Ben-Gurion Airport had concerns over rising South African tensions.

“The ability to reduce the burden of a critical illness, by providing an effective and well-tolerated vaccine with only one vaccination,” said Johnson’s Chief Scientific Officer Paul Stoffels. Johnson.

In addition, Johnson & Johnson plans to file for the Emergency Use Authority (EUA) as previous vaccine candidates – Pfizer and Modern.

The vaccine is, according to statistics, 85% effective overall in preventing serious complications that can lead to hospitalization.

The company noted that they would follow up with the trial participants “for two years”.

Leave a Reply

Your email address will not be published.